Boehringer, Vitae Partner On Alzheimer's Drugs

By: Associated Press Email
By: Associated Press Email

Stay up-to-date with KAKE News:

Monday, June 15, 2009

German drugmaker Boehringer Ingelheim and Vitae Pharmaceuticals say they are partnering to develop enzyme-inhibiting drugs with the potential to slow or even halt progression of Alzheimer's disease.

The deal could be worth roughly $250 million to Vitae, a small, development-stage pharmaceutical company based in Fort Washington, Pa.

The two companies will work together to develop drugs that block an enzyme called beta secretase, or BACE, involved in producing the amyloid-beta plaques that accumulate in the brains of Alzheimer's patients. Amyloid-beta peptide is a major part of those plaques, and is thought to be the key culprit in the development of Alzheimer's, a chronic neurodegenerative disorder that causes progressive memory loss.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
KAKE TV 1500 N. West Street Wichita, KS 67203-1323 (316) 943-4221
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 48079577 - kake.com/a?a=48079577